Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 102 publications
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer.
Journal: The New England journal of medicine
Published: May 27, 2026
Global prevalence of FGFR2b protein overexpression in advanced gastric cancer and gastroesophageal junction cancers: pooled analysis of two bemarituzumab phase III studies.
Journal: ESMO open
Published: December 17, 2025
2025 Canadian Surgery Forum: Sept. 17-20, 2025.
Journal: Canadian journal of surgery. Journal canadien de chirurgie
Published: December 09, 2025
Zanidatamab, a Dual HER2-Targeted Bispecific Antibody, in Patients with Unresectable Locally Advanced or Metastatic HER2-Positive Salivary Gland Cancer: A Combined Analysis of Early-Phase Studies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 20, 2025
Risk prediction model for brain metastasis risk among patients diagnosed with primary gastrointestinal cancers.
Journal: British journal of cancer
Published: October 12, 2025
Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 24, 2025
Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 24, 2025
PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 10, 2025
Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study.
Journal: The Lancet. Oncology
Published: March 24, 2025
Eastern Canadian Gastrointestinal Cancer Consensus Conference 2024.
Journal: Current oncology (Toronto, Ont.)
Published: February 15, 2025
Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial.
Journal: Nature communications
Published: November 20, 2024
Ramucirumab and paclitaxel in second or greater lines of therapy in patients with HER2-positive gastroesophageal cancer: a single center study.
Journal: The oncologist
Published: October 24, 2024
Last Updated: 09/26/2026